vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.

READING INTERNATIONAL INC is the larger business by last-quarter revenue ($50.3M vs $44.6M, roughly 1.1× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). READING INTERNATIONAL INC runs the higher net margin — -5.1% vs -90.4%, a 85.3% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs -14.2%). READING INTERNATIONAL INC produced more free cash flow last quarter ($4.1M vs $-19.9M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 5.6%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.

PACB vs RDI — Head-to-Head

Bigger by revenue
RDI
RDI
1.1× larger
RDI
$50.3M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+28.0% gap
PACB
13.8%
-14.2%
RDI
Higher net margin
RDI
RDI
85.3% more per $
RDI
-5.1%
-90.4%
PACB
More free cash flow
RDI
RDI
$24.1M more FCF
RDI
$4.1M
$-19.9M
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
5.6%
RDI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PACB
PACB
RDI
RDI
Revenue
$44.6M
$50.3M
Net Profit
$-40.4M
$-2.6M
Gross Margin
37.1%
Operating Margin
-92.3%
-1.9%
Net Margin
-90.4%
-5.1%
Revenue YoY
13.8%
-14.2%
Net Profit YoY
-1802.7%
-14.5%
EPS (diluted)
$-0.11
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
RDI
RDI
Q4 25
$44.6M
$50.3M
Q3 25
$38.4M
$52.2M
Q2 25
$39.8M
$60.4M
Q1 25
$37.2M
$40.2M
Q4 24
$39.2M
$58.6M
Q3 24
$40.0M
$60.1M
Q2 24
$36.0M
$46.8M
Q1 24
$38.8M
$45.1M
Net Profit
PACB
PACB
RDI
RDI
Q4 25
$-40.4M
$-2.6M
Q3 25
$-38.0M
$-4.2M
Q2 25
$-41.9M
$-2.7M
Q1 25
$-426.1M
$-4.8M
Q4 24
$2.4M
$-2.2M
Q3 24
$-60.7M
$-7.0M
Q2 24
$-173.3M
$-12.8M
Q1 24
$-78.2M
$-13.2M
Gross Margin
PACB
PACB
RDI
RDI
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
PACB
PACB
RDI
RDI
Q4 25
-92.3%
-1.9%
Q3 25
-101.1%
-0.6%
Q2 25
-112.8%
4.8%
Q1 25
-1154.5%
-17.2%
Q4 24
-390.1%
2.6%
Q3 24
-160.3%
-0.6%
Q2 24
-488.3%
-16.4%
Q1 24
-209.6%
-16.7%
Net Margin
PACB
PACB
RDI
RDI
Q4 25
-90.4%
-5.1%
Q3 25
-98.9%
-8.0%
Q2 25
-105.4%
-4.4%
Q1 25
-1146.8%
-11.8%
Q4 24
6.0%
-3.8%
Q3 24
-151.9%
-11.7%
Q2 24
-481.3%
-27.4%
Q1 24
-201.4%
-29.4%
EPS (diluted)
PACB
PACB
RDI
RDI
Q4 25
$-0.11
$-0.11
Q3 25
$-0.13
$-0.18
Q2 25
$-0.14
$-0.12
Q1 25
$-1.44
$-0.21
Q4 24
$-0.44
$-0.11
Q3 24
$-0.22
$-0.31
Q2 24
$-0.64
$-0.57
Q1 24
$-0.29
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
RDI
RDI
Cash + ST InvestmentsLiquidity on hand
$279.5M
$10.5M
Total DebtLower is stronger
$185.1M
Stockholders' EquityBook value
$5.3M
$-18.2M
Total Assets
$784.1M
$434.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
RDI
RDI
Q4 25
$279.5M
$10.5M
Q3 25
$298.7M
$8.1M
Q2 25
$314.7M
$9.1M
Q1 25
$343.1M
$5.9M
Q4 24
$389.9M
$12.4M
Q3 24
$471.1M
$10.1M
Q2 24
$509.8M
$9.3M
Q1 24
$561.9M
$7.5M
Total Debt
PACB
PACB
RDI
RDI
Q4 25
$185.1M
Q3 25
Q2 25
Q1 25
Q4 24
$202.7M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
PACB
PACB
RDI
RDI
Q4 25
$5.3M
$-18.2M
Q3 25
$36.1M
$-12.1M
Q2 25
$61.5M
$-7.7M
Q1 25
$91.6M
$-8.1M
Q4 24
$506.6M
$-4.4M
Q3 24
$453.1M
$1.6M
Q2 24
$492.7M
$6.5M
Q1 24
$649.0M
$18.0M
Total Assets
PACB
PACB
RDI
RDI
Q4 25
$784.1M
$434.9M
Q3 25
$803.2M
$435.2M
Q2 25
$825.5M
$438.1M
Q1 25
$860.8M
$441.0M
Q4 24
$1.3B
$471.0M
Q3 24
$1.5B
$495.7M
Q2 24
$1.5B
$494.9M
Q1 24
$1.7B
$494.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
RDI
RDI
Operating Cash FlowLast quarter
$-19.1M
$4.3M
Free Cash FlowOCF − Capex
$-19.9M
$4.1M
FCF MarginFCF / Revenue
-44.6%
8.2%
Capex IntensityCapex / Revenue
1.9%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$-2.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
RDI
RDI
Q4 25
$-19.1M
$4.3M
Q3 25
$-18.7M
$295.0K
Q2 25
$-29.4M
$1.6M
Q1 25
$-44.1M
$-7.7M
Q4 24
$-30.6M
$8.0M
Q3 24
$-45.5M
$1.3M
Q2 24
$-54.3M
$-10.4M
Q1 24
$-75.7M
$-2.8M
Free Cash Flow
PACB
PACB
RDI
RDI
Q4 25
$-19.9M
$4.1M
Q3 25
$-18.8M
$-246.0K
Q2 25
$-29.9M
$1.2M
Q1 25
$-45.4M
$-8.0M
Q4 24
$-32.3M
$7.0M
Q3 24
$-46.3M
$-1.1M
Q2 24
$-55.7M
$-10.6M
Q1 24
$-79.6M
$-4.7M
FCF Margin
PACB
PACB
RDI
RDI
Q4 25
-44.6%
8.2%
Q3 25
-48.9%
-0.5%
Q2 25
-75.3%
1.9%
Q1 25
-122.3%
-19.8%
Q4 24
-82.3%
12.0%
Q3 24
-115.7%
-1.8%
Q2 24
-154.8%
-22.7%
Q1 24
-205.0%
-10.4%
Capex Intensity
PACB
PACB
RDI
RDI
Q4 25
1.9%
0.3%
Q3 25
0.2%
1.0%
Q2 25
1.4%
0.6%
Q1 25
3.7%
0.6%
Q4 24
4.1%
1.7%
Q3 24
2.0%
4.0%
Q2 24
4.1%
0.5%
Q1 24
10.0%
4.3%
Cash Conversion
PACB
PACB
RDI
RDI
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

RDI
RDI

Cinema Exhibition Segment$46.9M93%
Real Estate Revenue$3.4M7%

Related Comparisons